| Identification | Back Directory | [Name]
2,4(1H,3H)-Pyrimidinedione, 5-ethynyl- (9CI) | [CAS]
59989-18-3 | [Synonyms]
GW-776
GW776C85
ADH-300004
NSC 687296
5-ethynyluracil
5-Ethynyluracil>
13C,15N2]-Eniluracil
Eniluracil (5-Ethynyluracil
5-Ethynyl-1H-pyrimidine-2,4-dione
5-EthynylpyriMidine-2,4(1H,3H)-dione
5-Ethynyl-2,4(1H,3H)-pyriMidinedione
2,4(1H,3H)-Pyrimidinedione, 5-ethynyl-
2,4(1H,3H)-Pyrimidinedione, 5-ethynyl- (9CI)
5-fluorouracil,cancer,Inhibitor,inhibit,Eniluracil,5-FU,tumor,combination | [Molecular Formula]
C6H4N2O2 | [MDL Number]
MFCD00871973 | [MOL File]
59989-18-3.mol | [Molecular Weight]
136.108 |
| Chemical Properties | Back Directory | [Melting point ]
320° (dec) | [density ]
1.527 | [storage temp. ]
under inert gas (nitrogen or Argon) at 2-8°C | [solubility ]
Soluble in DMSO | [form ]
solid | [pka]
7.44±0.10(Predicted) | [color ]
Yellow | [λmax]
284nm(MeOH)(lit.) | [Merck ]
14,3584 | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| Hazard Information | Back Directory | [Description]
Eniluracil (59989-18-3) is an irreversible dihydropyrimidine dehydrogenase (DPD) inhibitor.1-3? DPD is involved in the degradation of pyrimidine-based chemotherapeutic drugs such as 5-fluorouracil (5-FU).? Eniluracil has been used along with 5-FU to prolong circulating concentrations of the drug. | [Uses]
Potent inactivator of Dihydropyrimidine dehydrogenase (DPD). | [Definition]
ChEBI: Eniluracil is a pyrimidone. | [in vivo]
Eniluracil (5-Ethynyluracil) (1 mg/kg; i.p.; single daily for 3 days) exhibits neither toxicity nor intrinsic antitumor activity, and greatly improves FUra (5-fluorouracil) therapy in rats[1]. | Animal Model: | Female Fischer 344/HSD rats (6 to 7-week-old; 150-200 g)[1]. | | Dosage: | 1 mg/kg | | Administration: | Intraperitoneal injection; single daily for 3 days (l h before FUra (5-fluorouracil) and for an additional 2 days after FUra therapy) | | Result: | Produced complete tumor regression that was sustained for at least 90 days posttherapy when combined with 3.5 mg/kg FUra, however, 35 mg/kg FUra alone produced partial responses in 75% of the treated animals ( the tumors regrew in all of these animals). |
| [References]
1) Porter?et al. (1992),?Mechanism-based Inactivation of Dihydropyrimidine Dehydrogenase by 5-Ethynyluracil; J. Biol. Chem.,?267?5236
2) Baccalnari?et al. (1993),?5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil; Proc. Natl. Acad. Sci. USA,?90?11064
3) Schilsky and Kindler (2000)?Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase; Expert Opin. Investig. Drugs,?9?1635 |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
TCI Europe
|
| Tel: |
320-37350700 |
| Website: |
https://www.tcichemicals.com/de/de/index.html |
|